| 3-Deoxysappanchalcone isolated from Caesalpinia sinensis shows anticancer effects on HeLa and PC3 cell lines: invasion, migration, cell cycle arrest, and signaling pathway D Lv, Q Lai, Q Zhang, J Wang, Y Li, GZ Zeng, JL Yin Heliyon 8 (10), 2022 | 3 | 2022 |
| A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies DC Phillips, S Jin, GP Gregory, Q Zhang, J Xue, X Zhao, J Chen, Y Tong, ... Leukemia 34 (6), 1646-1657, 2020 | 64 | 2020 |
| A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, ... Nature medicine 25 (12), 1938-1947, 2019 | 408 | 2019 |
| Abstract A24: Targeting mitochondrial metabolism following Induction Chemotherapy eradicates Acute Myeloid Leukemia at the level of Minimal Residual Disease N Baran, L Han, L Stuani, A Cavazos, LM Cooper, CL Ramage, ... Blood Cancer Discovery 4 (3_Supplement), A24-A24, 2023 | | 2023 |
| Abstract LB-261: Targeting BET Family Bromodomain with ABBV-075 and BCL-2 with venetoclax (ABT-199) is synergistic in primary acute myeloid leukemia models T Cai, VM Kuruvilla, T Uziel, Q Zhang, L Han, A Cavazos, Y Shen, ... Cancer Research 78 (13_Supplement), LB-261-LB-261, 2018 | 2 | 2018 |
| Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia Q Zhang, B Riley-Gillis, L Han, Y Jia, A Lodi, H Zhang, S Ganesan, R Pan, ... Signal transduction and targeted therapy 7 (1), 51, 2022 | 72 | 2022 |
| AML Cells Alter Bone Homeostasis By Promoting the Formation of Immature Bone and Resorption of Mature Bone That Supports Leukemia Progression A Tyagi, B Yuan, S Ly, F El-Dana, VM Kuruvilla, Q Zhang, CB Peterson, ... Blood 136, 27, 2020 | | 2020 |
| AML-242: Osteoprogenitor Cells, but Not Mature Osteoblasts/Osteocytes that Support AML Growth in the Bone Marrow Microenvironment A Tyagi, B Yuan, S Ly, F El-Dana, V Kuruvilla, Q Zhang, X Zhou, ... Clinical Lymphoma Myeloma and Leukemia 20, S195, 2020 | | 2020 |
| AML-367: IMGN632, a CD123-targeting ADC bearing a DNA-alkylating IGN payload, combines effectively as a triplet regimen with azacitidine and venetoclax in vivo, prolonging … V Kuruvilla, R McCarthy, Q Zhang, K Watkins, S Adams, C Sloss, ... Clinical Lymphoma Myeloma and Leukemia 20, S208-S209, 2020 | 1 | 2020 |
| An inhibitor of oxidative phosphorylation exploits cancer vulnerability JR Molina, Y Sun, M Protopopova, S Gera, M Bandi, C Bristow, T McAfoos, ... Nature medicine 24 (7), 1036-1046, 2018 | 733 | 2018 |
| Analysis of tumor lysis syndrome in 380 cases of acute leukemia Q Zhang, KQ Liu, BC Liu, CL Zhou, W Li, D Lin, Y Wang, YC Mi, JX Wang Zhongguo shi yan xue ye xue za zhi 23 (1), 61-64, 2015 | 5 | 2015 |
| Anti-leukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123 antibody-conjugate in acute myeloid leukemia L Han, E Rowinsky, C Brooks, C Shi, Q Zhang, J Burks, J Zhou, H Mu, ... Clinical Lymphoma, Myeloma and Leukemia 15, S14, 2015 | 1 | 2015 |
| Antileukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123 antibody conjugate, in acute myeloid leukemia L Han, JL Jorgensen, C Brooks, C Shi, Q Zhang, GM Nogueras González, ... Clinical Cancer Research 23 (13), 3385-3395, 2017 | 44 | 2017 |
| BCL-2 Antagonist ABT-199 Combined with Complex I Inhibitor IACS-010759 Blocks Mitochondrial Respiration and Facilitates Anti-Leukemia Efficacy in Pre-Clinical AML Models Q Zhang, L Han, T Cai, VM Kuruvilla, A Cavazos, H Ma, VL Battula, ... Blood 130, 1362, 2017 | 3 | 2017 |
| BCL-2 Inhibition with ABT-199 Shows Efficacy in AML Cell Lines with Synergistic Effects upon Addition of the MEK Inhibitor GDC-0973 and Prolongs Survival in an NAS/BCL-2 … RA Padua, M Chiquet, Q Zhang, C Kappel, P Krief, N Setterblad, ... Blood 130, 2613, 2017 | | 2017 |
| Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells Y Jia, L Han, CL Ramage, Z Wang, CC Weng, L Yang, S Colla, H Ma, ... Haematologica, 2023 | 13 | 2023 |
| Combination Therapy of FLT3 Tyrosine Kinase Inhibitors and BH3 Mimetics Targeting Antiapoptotic MCL-1 Synergistically Eliminates FLT3-ITD Acute Myeloid Leukemia Cells in Vitro … A Skwarska, DM Moujalled, PF Panis, S Patel, Q Zhang, S Herbrich, ... Blood 138, 2248, 2021 | | 2021 |
| Combined blockade of CD47-Sirpa interaction by 5F9 (magrolimab) and azacitidine/venetoclax therapy facilitates macrophage-mediated anti-leukemia efficacy in AML pre-clinical models Y Jia, Q Zhang, C Weng, CL Ramage, Y Nishida, M Chao, RL Maute, ... Blood 138, 510, 2021 | 16 | 2021 |
| Combined targeting of JAK2 with a type II JAK2 inhibitor and mTOR with a TOR kinase inhibitor constitutes synthetic activity in JAK2-driven Ph-like acute lymphoblastic leukemia C Shi, L Han, Q Zhang, KG Roberts, E Park, Y Tabe, RO Jacamo, H Mu, ... Blood 126 (23), 2529, 2015 | 6 | 2015 |
| Combining IMGN632, a novel CD123-targeting antibody drug conjugate with azacitidine and venetoclax facilitates apoptosis in vitro and prolongs survival in vivo in AML models VM Kuruvilla, Q Zhang, N Daver, K Watkins, CM Sloss, ... Blood 136, 32-33, 2020 | 5 | 2020 |
Michael AndreeffUT MD Anderson Cancer Center在 mdanderson.org 的电子邮件经过验证
